9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

Core Clinical Competency: The Advanced Practice Registered Nurse (APRN) must manage acute traumatic and postoperative pain in patients maintained on Medications for Opioid Use Disorder (MOUD). The APRN must apply precise neuropharmacological principles, debunk clinical myths regarding pain tolerance, navigate competitive opioid receptor dynamics, and prevent both undertreated agony and iatrogenic withdrawal.

---

1. Cardinal Clinical Principles of Acute Pain in MOUD Patients

Managing acute traumatic, surgical, or medical pain in patients receiving MOUD requires advanced understanding of neuroadaptation, opioid cross-tolerance, and receptor kinetics. Three cardinal principles guide evidence-based care:

Three Cardinal Principles of Acute Pain Management in MOUD:

┌─────────────────────────────────────────────────────────────────────────┐
│ Principle 1: MOUD Does NOT Provide Analgesia for Severe Acute Pain     │
│ • Chronic maintenance satisfies physical dependence and suppresses     │
│   cravings, but analgesic duration is only 4 to 8 hours.                │
└────────────────────────────────────┬────────────────────────────────────┘
                                     ▼
┌─────────────────────────────────────────────────────────────────────────┐
│ Principle 2: Opioid Tolerance Mandates Higher Doses at Shorter Intervals│
│ • Downregulated mu receptors and cross-tolerance require 1.5x to 3x     │
│   higher doses of full agonists administered every 2 to 3 hours.        │
└────────────────────────────────────┬────────────────────────────────────┘
                                     ▼
┌─────────────────────────────────────────────────────────────────────────┐
│ Principle 3: NEVER Withhold or Abruptly Discontinue Baseline MOUD       │
│ • Discontinuation triggers catastrophic withdrawal, hyperalgesia,       │
│   autonomic instability, and heightened risk of illicit relapse.        │
└─────────────────────────────────────────────────────────────────────────┘

Clinical Myth vs. Neurobiological Reality

• Myth 1: "The patient's daily methadone or buprenorphine dose covers their acute pain."
  • Reality: While the terminal half-life of methadone (15–60 hours) and buprenorphine (24–42 hours) suppresses withdrawal and cravings for 24 to 36+ hours, the duration of active analgesia is only 4 to 8 hours. Patients on stable once-daily MOUD experience zero baseline analgesic protection against new acute tissue trauma.
• Myth 2: "Providing full agonist opioids to an MOUD patient will trigger an immediate addiction relapse."
  • Reality: Undertreating severe acute pain creates a massive hyperadrenergic surge, severe suffering, and intense craving, drastically increasing the risk of illicit drug acquisition. Relieving acute pain compassionately and adequately with scheduled analgesics stabilizes the patient and protects recovery.
• Myth 3: "High opioid requests represent drug-seeking behavior or pseudoaddiction."
  • Reality: Chronic opioid exposure causes profound neurobiological desensitization and downregulation of central mu-opioid receptors. These patients exhibit genuine pharmacological cross-tolerance and require substantially higher doses of full agonists to achieve equivalent antinociception. Behaviors driven by undertreated agony represent pseudoaddiction, which resolves promptly when adequate analgesia is delivered.

---

2. Clinical Protocol: Acute Pain Management in Methadone Maintenance

Patients enrolled in Opioid Treatment Programs (OTPs) receiving daily methadone maintenance require careful coordination across inpatient and outpatient care.

Acute Pain Protocol in Methadone Maintenance:

[Patient on Methadone Maintenance Admitted for Acute Pain / Surgery]
                                 │
                                 ▼
[1. Verification of Baseline Dose]
• Contact OTP directly or verify via PDMP / secure hospital records
• Document exact dose, date/time of last dose, and OTP contact details
                                 │
                                 ▼
[2. Maintenance Dose Continuation]
• CONTINUE full verified methadone dose throughout hospitalization
• Administer as scheduled (federal regulations explicitly allow inpatient
  methadone maintenance for acute medical/surgical conditions)
                                 │
                                 ▼
[3. Acute Breakthrough Analgesia]
• Multi-modal baseline: IV acetaminophen + IV ketorolac (if not contraindicated)
• Add scheduled or PRN short-acting full agonist (IV hydromorphone, IV morphine,
  or oral oxycodone)
• Dosing: 1.5x to 3x higher than opioid-naive doses; shorten dosing interval
  (e.g., q2-3h instead of q4-6h)
                                 │
                                 ▼
[4. Alternative / Adjunctive Strategy: Methadone Dose-Splitting]
• In consultation with pain service, divide daily baseline methadone into
  equal TID or QID doses (e.g., 30 mg q8h instead of 90 mg once daily)
• Harnesses methadone's 6- to 8-hour analgesic duration for continuous baseline relief

Clinical Steps & Federal Regulations

1. OTP Verification: Immediately contact the patient's OTP to confirm the exact daily dose and time of the last dose. Federal law (Title 21, Code of Federal Regulations, Part 1306.07[c]) explicitly allows acute care hospitals to administer methadone to maintain maintenance therapy during medical or surgical admissions.
2. Continue Verified Baseline Dose: Never hold or reduce the baseline dose. If the patient is NPO, administer the baseline dose parenterally (intravenous or subcutaneous methadone conversion: 50% of oral dose, divided into two to three daily doses due to higher parenteral bioavailability).
3. Breakthrough Analgesia with Short-Acting Full Agonists: Prescribe scheduled or PRN immediate-release full mu agonists (hydromorphone, fentanyl, oxycodone, morphine). Titrate aggressively to clinical comfort. Opioid-tolerant patients require doses 50% to 200% higher than standard opioid-naive parameters, with narrowed intervals (every 2 to 3 hours).
4. Methadone Dose-Splitting Strategy: Because methadone provides analgesia for only 6 to 8 hours, dividing the patient's verified total daily dose into three or four divided doses (e.g., every 6 or 8 hours) harnesses methadone's intrinsic antinociceptive properties, establishing continuous baseline relief.

---

3. Clinical Protocol: Acute Pain Management in Buprenorphine Maintenance

Buprenorphine Acute Pain Paradigm Shift:

[HISTORICAL PRACTICE - RETIRED / HARMFUL]:
Discontinue buprenorphine 48-72 hours pre-op ──> Patient enters acute withdrawal,
severe pain, hemodynamic instability, delayed recovery, and high relapse risk!

[MODERN EVIDENCE-BASED PRACTICE - ASAM / ASA GUIDELINES]:
CONTINUE Buprenorphine Maintenance Throughout the Perioperative Period!
                                │
             ┌──────────────────┼──────────────────┐
             ▼                  ▼                  ▼
      [Pathway A]          [Pathway B]        [Pathway C]
      Continue Baseline    Split Baseline     Dose Escalation
      Buprenorphine &      Buprenorphine into Buprenorphine PRN
      Add Full Agonists    Divided Doses      (Add 2-4 mg SL q4-6h
      (Titrate IV Fentanyl (e.g., 8 mg TID    up to 24-32 mg/day)
      or Hydromorphone)    or 4 mg QID)       Ideal for mild/mod
      Ideal for severe     Ideal for moderate acute surgical pain
      major surgical pain  inpatient pain

Retirement of the Historical Practice

Historically, surgeons and anesthesiologists instructed patients to stop buprenorphine 3 to 5 days prior to surgery, fearing that its high mu-receptor affinity ($K_i \approx 0.219\text{ nM}$) would prevent full agonist opioids from binding. This practice is now completely retired. Abrupt discontinuation precipitates acute withdrawal, heightens surgical stress, induces neuroendocrine instability, and leaves the patient vulnerable to severe postoperative pain that is difficult to manage.

Modern ASAM and ASA Endorsed Pathways

1. Pathway A (Continue Baseline Buprenorphine and Add High-Affinity Full Agonists):
   • Continue the patient's baseline buprenorphine dose (e.g., 16 mg daily).
   • At 16 mg/day, buprenorphine occupies approximately 80% to 85% of mu-opioid receptors, leaving 15% to 20% unoccupied.
   • Administer high-potency, high-affinity full mu agonists (intravenous fentanyl or hydromorphone) titrated to effect. These agents bind to remaining unoccupied receptors and, at higher concentrations, compete with and overcome buprenorphine binding to provide robust acute antinociception.
   • Advantage: Zero withdrawal risk; rapid transition back to standard maintenance upon discharge without re-induction.
2. Pathway B (Split Baseline Buprenorphine into Divided Doses):
   • Divide the patient's daily maintenance dose into TID or QID dosing (e.g., a patient on 24 mg daily receives 8 mg SL every 8 hours; a patient on 16 mg daily receives 4 mg SL every 6 hours).
   • Buprenorphine is a potent analgesic, but its analgesic effect lasts only 6 to 8 hours. Dividing the daily dose provides steady, 24-hour baseline analgesia.
3. Pathway C (Supplemental Buprenorphine Dosing):
   • In patients experiencing mild-to-moderate acute pain, add supplemental buprenorphine (e.g., 2 mg to 4 mg SL every 4 to 6 hours PRN) up to a maximum daily ceiling of 24 mg to 32 mg/day.

---

4. Clinical Protocol: Acute Pain Management in Naltrexone Maintenance

Naltrexone is a pure, insurmountable competitive mu-opioid receptor antagonist with an extraordinarily high binding affinity. It renders standard doses of full-agonist opioids completely clinically ineffective.

Naltrexone Perioperative & Emergency Management Algorithm:

                     [Patient on Naltrexone Maintenance]
                                     │
                ┌────────────────────┴────────────────────┐
                ▼                                         ▼
     [Elective / Scheduled Surgery]             [Emergency Surgery / Acute Trauma]
     • Oral Naltrexone:                         • Naltrexone is ACTIVELY BLOCKING!
       Discontinue ≥72 hours pre-op             • Standard opioids will FAIL!
     • Extended-Release IM (Vivitrol):                            │
       Schedule surgery at week 4 nadir                           ▼
       (28-30 days post-injection)              [Multi-Modal & Regional First-Line]
                                                • Neuraxial / Peripheral nerve blocks
                                                • IV Ketamine infusion (0.1-0.3 mg/kg/h)
                                                • IV Acetaminophen + IV Ketorolac
                                                                  │
                                                                  ▼
                                                [If Opioids Clinically Mandatory]
                                                • High-potency opioids (Fentanyl)
                                                • Administer in ICU / Monitored PACU
                                                • Continuous Capnography & Telemetry
                                                • Mechanical ventilator on standby!
                                                *Extreme risk of delayed apnea!*

Elective / Scheduled Procedures

• Oral Naltrexone (ReVia): Must be discontinued at least 72 hours (3 days) prior to elective surgery to ensure complete receptor dissociation.
• Injectable Extended-Release Naltrexone (Vivitrol 380 mg IM): Schedule elective surgery at the end of the 28-day dosing cycle (ideally weeks 4 to 5 post-injection), when plasma concentrations have declined below therapeutic antagonist levels.

Emergency Surgery & Acute Severe Trauma (Active Naltrexone Blockade)

When a patient experiences severe acute trauma or requires emergency surgery while naltrexone is actively bound to mu-opioid receptors, the APRN and surgical team must execute a specialized protocol:

1. Aggressive Regional and Neuraxial Anesthesia: Maximize spinal anesthesia, epidural analgesia, and ultrasound-guided peripheral nerve blocks utilizing local anesthetics (e.g., bupivacaine, ropivacaine) which bypass opioid receptors entirely.
2. Systemic Non-Opioid Infusions: Initiate an intravenous ketamine infusion (0.1 mg to 0.3 mg/kg/hour) to provide potent N-methyl-D-aspartate (NMDA) receptor antagonism, alongside IV acetaminophen and IV NSAIDs (ketorolac).
3. Overcoming Competitive Blockade (High-Potency Opioids in Monitored ICU Setting):
   • If opioid analgesia is unavoidable, the clinician must administer high-affinity, high-potency synthetic opioids (intravenous fentanyl or sufentanil) at doses sufficient to competitively displace naltrexone from central mu receptors.
   • MANDATORY CRITICAL CARE SAFEGUARD: Overcoming competitive naltrexone blockade requires substantially higher opioid doses than normal. As the opioid overcomes the antagonist, or as naltrexone rapidly dissociates, the patient is at extreme risk for sudden, catastrophic, delayed respiratory depression and fatal apnea.
   • This therapy must only be conducted in an Intensive Care Unit (ICU), Post-Anesthesia Care Unit (PACU), or emergency resuscitation bay with continuous capnography (end-tidal CO2), continuous electrocardiographic telemetry, pulse oximetry, and immediate access to advanced airway equipment and mechanical ventilation.

---

5. Post-Discharge Planning, Care Coordination & MOUD Resumption

Discharge Planning & MOUD Coordination Flowchart:

[Acute Surgical / Inpatient Phase Resolves]
                     │
                     ▼
[1. Taper & Discontinue Acute Full Agonists]
• Taper short-acting opioids rapidly as tissue heals (3-5 day maximum outpatient supply)
• Do NOT provide prolonged full agonist prescriptions to patients on MOUD
                     │
                     ▼
[2. Transition Back to Outpatient MOUD Provider]
• Direct clinician-to-clinician sign-out with OTP (Methadone) or OBOT (Buprenorphine)
• Confirm verified discharge medications, date of last dose, and next outpatient visit
                     │
                     ▼
[3. Specialized Protocol for Resuming Naltrexone]
• Mandatory Opioid Washout: Must be entirely opioid-free for 7 to 10 days
  (short-acting opioids) or 14 days (buprenorphine/methadone)
• Verify negative UDT (including fentanyl/methadone)
• Perform Naloxone Challenge Test (0.4 mg IV/SC) to confirm zero physical dependence
• If challenge is negative, restart oral naltrexone 25-50 mg daily or administer IM Vivitrol

Methadone and Buprenorphine Discharge Continuity

• Contact the outpatient OTP or buprenorphine provider prior to discharge. Provide formal documentation of all medications administered during hospitalization.
• Discontinue inpatient short-acting breakthrough opioids prior to or at discharge. If severe post-discharge surgical pain persists, provide a strictly limited supply (e.g., 3 to 5 days maximum of short-acting full agonist) with close outpatient follow-up.

Resuming Naltrexone Maintenance

Patients whose naltrexone was stopped for surgery or who received full-agonist opioids require careful re-induction. Administering naltrexone prematurely precipitates severe, life-threatening withdrawal:

• Drug-Free Clearance Interval: The patient must be completely abstinent from all short-acting opioids for a minimum of 7 to 10 days, and from long-acting opioids (methadone, buprenorphine) for at least 14 days.
• Urine Toxicology: Obtain a definitive laboratory UDT confirming absence of opioids.
• Naloxone Challenge Test: Administer an initial test dose of naloxone 0.4 mg IV or SC; monitor for 30 to 60 minutes for objective signs of withdrawal (tachycardia, diaphoresis, piloerection). If no withdrawal occurs, it is safe to resume oral naltrexone (25 mg Day 1, then 50 mg daily) or administer extended-release intramuscular naltrexone (Vivitrol 380 mg IM).

---

6. MOUD Acute Pain Management Clinical Comparison Matrix